RANCHO CORDOVA, Calif.,
June 26, 2019 /PRNewswire/
-- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in
automated cell processing and autologous cell therapies for
regenerative medicine, today announced that on June 25, 2019 the Company received notification
from the Qualifications Department of The Nasdaq Stock Market
("Nasdaq") that it has regained compliance with Nasdaq Listing Rule
5550(a)(2), which concerns minimum bid price listing
requirements. The Company's shares will continue to be traded
on The Nasdaq Stock Market under the Symbol KOOL.
"We are pleased to be in full compliance with these continued
listing standards," said Chris Xu,
Cesca's Chief Executive Officer. "We can now put this behind us and
work hard to ensure that our share price continues to appreciate in
response to our ongoing business growth and success."
About Cesca Therapeutics Inc.
Cesca Therapeutics
Inc. is a market leader in cell processing technologies and
autologous cell therapies for regenerative medicine. For more
information, visit: www.cescatherapeutics.com.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in
such statements. A more complete description of risks that could
cause actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' Annual Report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-regains-nasdaq-listing-compliance-300875063.html
SOURCE Cesca Therapeutics Inc.